Novel opioids in postoperative pain management

Potapov A.L.

doi:https://doi.org/10.17116/anaesthesiology202503178

Recommended articles:

Effect of selective opioid agonist taphalgin on the risk of nausea and vomiting after thyroid surgery in young non-smoking females. Russian Journal of Anesthesiology and Reanimatology. 2025;(5):37-41

Reflexotherapy as an effective component of postoperative pain relief. Russian Journal of Pain. 2024;(4):41-45

Psychosensory anatomo-functional autodesadaptation syndrome as a predictor of pain in patients after orthognathic surgery. Russian Rhinology. 2025;(1):42-47

Use of a fixed combination of diclofenac and orphenadrine (Neodolpasse) for postoperative analgesia after extended gastrectomy with resection of the lower third of the esophagus. P.A. Herzen Journal of Oncology. 2025;(2):52-56

New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics. P.A. Herzen Journal of Oncology. 2025;(5):73-77

Abstract:

Postoperative pain management remains unsatisfactory. Thus, searching for new methods of adequate pain control is still important. This review is devoted to novel opioids for postoperative analgesia. These opioids have comparable and even greater effectiveness compared to traditional opioid analgesics with lower rate of adverse side effects. This is achieved due to new capabilities, i.e. antagonism with β-arrestin (oliceridine), noradrenaline reuptake inhibition (tapentadol), impact on nociceptin/orphanin receptors (cebranopadol), significant prolongation of duration of action (dinalbuphine), high selectivity to type 1 µ-receptors (tafalgin), impact on concentration of endogenous opioid peptides (DENKIs, CYT-1010). Data from experimental and clinical studies are presented for each drug. Despite development of opioid-sparing techniques, opioid analgesics keep their place in the treatment of pain after surgery. Some novel opioids (tapentadol, tafalgin) are available In Russia.

Keywords:

postoperative pain

opioids

oliceridine

tapentadol

cebranopadol

dinalbuphine

dual enkephalinase inhibitors

endomorphin-1

tafalgin

Authors:

Potapov A.L.

Tsyba Medical Radiological Research Center

ORCID: 0000-0003-3752-3107

Received:

15.07.2024

Accepted:

19.09.2024

Close metadata

References:

Ovechkin AM, Bayalieva AZh, Ezhevskaya AA, Eremenko AA, Zabolotsky DV, Zabolotskikh IB, Karelov AE, Koryachkin VA, Spasova AP, Khoronenko VE, Uvarov DN, Ulrich GE, Shadrin RV. Postoperative analgesia. Guidelines. Annals of Critical Care. 2019; 4:9-33. (In Russ.). https://doi.org/10.21320/1818-474x-2019-4-9-33
Van Boekel RLM, Warlé MC, Nielen RGC, Vissers KCP, van der Sande R, Bronkhorst EM, Lerou JGC, Steegers MAH. Relationship between Postoperative Pain and Overall 30-Day Complications in a Broad Surgical Population: An Observational Study. Annals of Surgery. 2019;269(5):856-865. https://doi.org/10.1097/sla.0000000000002583
Lirk P, Rathmell JP. Opioid-free anaesthesia: Con: it is too early to adopt opioid-free anaesthesia today. European Journal of Anesthesiology. 2019;36(4): 250-254. https://doi.org/10.1097/EJA.0000000000000965
Schug SA, Scott DA, Mott JF, Halliwell R, Palmer GM, Alcock M. APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence. 5th edition. ANZCA & FPM; Melbourne; 2020.
Ovechkin AM, Efremenko IV. Influence of various methods of anesthesia and analgesia on long-term results of surgical in oncology. Vestnik natsional’nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova. 2012;7(4): 100-105. (In Russ.).
Potapov AL, Boyarkina AV. Role of μ1-opioid receptor and its genetic polymorphism in patients with cancers. Oncologiya. Zhurnal im. P.A. Gertsena. 2016;5(3):76-79. (In Russ.).
Bol’. Prakticheskoe rukovodstvo. Yakhno NN, ed. 2-e izd. M.: MEDpress-inform; 2023. (In Russ.).
Arbuck DM, Abuzarova GR, Alekseeva GS. Opioids in Pain Syndrome Management (part 1). Messenger of Anesthesiology and Resuscitation. 2017; 14(3):58-67. (In Russ.). https://doi.org/10.21292/2078-5658-2017-14-3-58-67
Gein SV, Baeva TA. Endomorphins: Structure, Localoisation, Immunoregulatory Activity. Problemy endokrinologii. 2020;66(1):78-86. (In Russ.). https://doi.org/10.14341/probl10364
Bunzow JR, Saez C, Mortrud M, Williams JT, Low M, Grandy DK. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Letters. 1994;347(2-3):284-288. https://doi.org/10.1016/0014-5793(94)00561-3
Shamakina IYu, Shagiakhmetov FS, Anokhin PK, Kokhan VS, Davydova TV. The role of nociception in opioid regulation of brain functions. Biomeditsinskaya khimiya. 2021;67(1):5-16. (In Russ.). https://doi.org/10.18097/PBMC20216701005
Dmitrievskaya MI, Sereda EV. Opioid receptors: opportunities and prospects. Astrakhanskij meditsinskij zhurnal. 2020;15(3):16-23. (In Russ.).
Food and Drug Administration (FDA). Highlights of Prescribing Information — Olinvyk (Oliceridine). Accessed March 18, 2025. https://www.accessdata.fda.gov
Dafsla N, Wang A, Jin Z, Gupta A, Bergese SD. Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review. Drug Design, Development and Therapy. 2023;17:875-886. https://doi.org/10.2147/DDDT.S372612
Bergese SD, Brzezinski M, Mammer GB, Beard TL, Pan PH, Mace SE, Berkowitz RD, Cochrane K, Wase L, Minkowitz HS, Habib AS. ATHENA: A Phase 3, Open-Label Study of the Safety and Effectiveness of Oliceridine (TRV130), A G-Protein Selective Agonist at the µ-Opioid Receptor, in Patients With Moderate to Severe Acute Pain Requiring Parenteral Opioid Therapy. Journal of Pain Research. 2019;12:3113-3126. https://doi.org/10.2147/JPR.S217563
Bergese S, Berkowitz R, Rider P, Ladouceur M, Griffith S, Vasi AS, Cochrane K, Wase L, Demitrack MA, Habib AS. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis. Pain Research and Management. 2020;2020:7492865. https://doi.org/10.1155/2020/7492865
Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Paleksiya. (In Russ.). Accessed March 18, 2025. https://grls.minzdrav.gov.ru
Nikoda VV. Tapentadol in Acute Pain: A Review of the Results of International Studies. Sovremennaya revmatologiya. 2021;15(4):113-119. (In Russ.). https://doi.org/10.14412/1996-7012-2021-4-113-119
Wang X, Narayan SW, Penm J, Patanwala AE. Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-Analysis. Clinical Journal of Pain. 2020;36(5):399-409. https://doi.org/10.1097/AJP.0000000000000809
Sorokina LS, Fomina DV, Semenkova MF, Eremenko FF. Efficiency and Safety of Tapentadol with Immediately Release for Postoperative Analgesia in Cardiac Surgery. Messenger of Anesthesiology and Resuscitation. 2023;20(3):45-51. (In Russ.). https://doi.org/10.24884/2078-5658-2023-20-3-45-51
Kleideiter E, Piana C, Wang S, Nemeth R, Gautrois M. Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic. Clinical Pharmacokinetics. 2018;57(1):31-50. https://doi.org/10.1007/s40262-017-0545-1
Dahan A, Boom M, Sarton E, Hay J, Groeneveld GJ, Neukirchen M, Bothmer J, Aarts L, Olofsen E. Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers. Anesthesiology. 2017;126(4):697-707. https://doi.org/10.1097/ALN.0000000000001529
Gohler K, Sokolowska M, Schoedel KA, Nemeth R, Kleideiter E, Szeto I, Eerdekens M. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study. Journal of Clinical Psychopharmacology. 2019;39(1):46-56. https://doi.org/10.1097/JCP.0000000000000995
Scholz A, Bothmer J, Kok M, Hoschen K, Daniels S. Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain. Pain Physician. 2018;21(3): E193-E206.
Wang A, Murphy J, Shteynman L, Daksla N, Gupta A, Bergese S. Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review. Pharmaceuticals (Basel). 2023;17(1):29. https://doi.org/10.3390/ph17010029
Zeng Z, Lu J, Shu C, Chen Y, Guo T, Wu Q, Yao S, Yin P. A comparision of nalbuphine with morphine for analgesic effects and safety: meta-analysis of randomized controlled trials. Scientific Reports. 2015;5:10927. https://doi.org/10.1038/srep10927
Tien YE, Huang W, Kuo H, Tai L, Uang Y, Chern WH, Huang J. Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation. Biopharm. Biopharmaceutics and Drug Disposition. 2017;38(8):494-497. https://doi.org/10.1002/bdd.2088
Yeh C, Jao S, Chen J, Fan C, Chen H, Hsieh P, Wu C, Lee C, Kuo Y, Hsieh M, Huang W, Chung Y, Liou T, Chiu H, Tseng W, Lee K, Wang J. Sebacoyl Dinalbuphine Ester Extended-release Injection for Long-acting Analgesia: A Multicenter, Randomized, Double-Blind, And Placebo-controlled Study in Hemorrhoidectomy Patients. Clinical Journal of Pain. 2017;33(5):429-434. https://doi.org/10.1097/AJP.0000000000000417
Lee YE, Wang SY, Chen JH, Chen CY, Shiue YL, Soong TC, Lam CF. Efficacy and Safety of Parenteral Injection of an Extended Release κ-receptor Opioid Sebacoyl Dinalbuphine Ester for Acute and Chronic Pain After Laparoscopic Bariatric Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial. Obesity Surgery. 2023;33(4):1192-1201. https://doi.org/10.1007/s11695-023-06502-9
Chang T, Huang C, Su W, Tsai H, Ma C, Yeh Y, Chen Y, Li C, Cheng K, Su M, Wang J. Extended-Release Dinalbuphine Sebacate Versus Intravenous Patient-Controlled Analgesia with Fentanyl for Postoperative Moderate-to-Severe Pain: A Randomized Controlled Trial. Pain and Therapy. 2020;9(2):671-681. https://doi.org/10.1007/s40122-020-00197-x
Alvarez-Perez B, Poras H, Maldonado R. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders. British Journal of Pharmacology. 2023;180(7):879-893. https://doi.org/10.1111/bph.15656
Sitbon P, Van Elstraete A, Hamdi L, Juarez-Perez V, Mazoit J, Benhamou D, Rougeot C. STR-324, a Stable Analog of Opiorphin, Causes Analgesia in Postoperative Pain by Activating Endogenous Opioid Receptor-dependent Pathways. Anesthesiology. 2016;125(5):1017-1029. https://doi.org/10.1097/ALN.0000000000001320
Moss LM, Berends CL, van Brummelen EMJ, Kamerling IMC, Klaassen ES, Bergmann K, Ville V, Juarez-Perez V, Benichou A, Groeneveld GJ. First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management. British Journal of Clinical Pharmacology. 2022;88(1):103-114. https://doi.org/10.1111/bcp.14931
Webster L, Schmidt WK. Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach. Pain Medicine. 2019;21(5):992-1004. https://doi.org/10.1093/pm/pnz122
Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Tafalgin. (In Russ.). Accessed March 18, 2025. https://grls.minzdrav.gov.ru
Kosorukov VS, Abuzarova GR, Zakharochkina ER, Gamzeleva OYu, Yatsenko KA. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei. 2022;12(2):89-107. (In Russ.). https://doi.org/10.17650/2222-1468-2022-12-2-89-107
Karelov AE, Kosorukov VS, Kraevskaya YuN, Buyanova SN, Petrakova SA, Klimashevich AV, Filimonov VB, Gorelov VP, Syrovatskiy AA, Belyaeva NA, Aleksandrov MI, Rodoman GV. Effectiveness of the new peptide analgesic Tafalgin in the treatment of postoperative pain. Russian Journal of Anesthesiology and Reanimatology. 2023;6:75-83. (In Russ.). https://doi.org/10.17116/anaesthesiology202306175